Press Releases Endonovo Reports Pre-Clinical Data
Post# of 416
(Total Views: 526)
Posted On: 02/01/2018 9:43:23 AM
Press Releases
Endonovo Reports Pre-Clinical Data Demonstrating Immunotronics™ Reduced Infarct Size and Inhibited Fibrosis following Myocardial Infarction
LOS ANGELES, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
,
a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced positive results from a study of post-myocardial infarction remodeling in mice.
In the study, animals treated with the Company's non-invasive medical device one or two times per day for 28 days had significantly smaller (by 36.4%, p<0.01) infarcts versus the controls. Furthermore, animals treated with Pulsed Electromagnetic Fields (PEMF) one or two times per day for 28 days demonstrated significantly less cardiac fibrosis than the controls.
Blood levels of Brain Natriuretic Peptide (BNP), a hormone secreted by cardiomyocytes in the heart in response to volume expansion and pressure overload, were significantly higher in animals treated two times per day with PEMF versus the controls. Natriuretic peptides have been shown to be Cardioprotective, anti-fibrotic and paracrine regulators of vascular regeneration. The Company is currently conducting a follow-up study to elucidate a possible mechanism of action of PEMF treatment. Specifically, the Company is examining if PEMF treatment promotes cardiomyocyte survival and wound repair (angiogenesis), and inhibits excessive inflammation in the infarcted heart.
The Company had previously announced initial pre-clinical data demonstrating Immunotronics™ significantly improved cardiac function, including ejection fraction and fractional shortening, and reduced ventricular remodeling in infarcted animals following myocardial infarction.
Left ventricular (LV) remodeling after myocardial infarction (MI) includes infarct expansion and hypertrophy of the non-infarcted myocardium, fibrosis, LV chamber dilatation, LV functional deterioration and progression to heart failure. Treatments targeting the remodeling process, such as beta-blockers and angiotensin converting enzyme inhibitors have been shown to improve LV function as well as long term survival. However, a slow progression to chronic heart failure continues with large transmural MI as the loss of infarcted tissue and volume overload (chamber dilation) is often out of proportion to the hypertrophic response. Therefore, new treatments that can further improve the remodeling process are critical for preventing heart failure following MI.
"We are truly astounded by the results of this study to evaluate the effectiveness of our Electroceuticals in improving heart function and reducing ventricular remodeling following MI," stated Endonovo CEO, Alan Collier.
"Our team has seen the benefits of non-invasive Electroceuticals in a clinical setting in patients with end-stage ischemic heart disease using our 27.12 MHz tPEMF platform. We have now taken over twenty years of research and development and have created a new technology that we believe is a more effective treatment for cardiovascular disease."
"We believe bioelectronic medicine is the future and our non-invasive Electroceuticals™ are at the forefront of this emerging field of medicine seeking to treat some of our largest causes of death, including cardiovascular and cerebrovascular disease with technology rather than drugs," concluded Mr. Collier.
The Company has posted an updated presentation containing the results of its pre-clinical study on the Presentations section of its website.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ addresses wound healing, pain, post surgical edema and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ device using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease, cardiovascular and peripheral artery disease. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108
Sbarnes@endonovo.com
www.endonovo.com
Source: Endonovo Therapeutics, Inc.
Investors: Sign Up for Email Alerts on Endonovo
Primary Logo
Source: Endonovo Therapeutics, Inc.
Released February 1, 2018
Endonovo Reports Pre-Clinical Data Demonstrating Immunotronics™ Reduced Infarct Size and Inhibited Fibrosis following Myocardial Infarction
LOS ANGELES, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced positive results from a study of post-myocardial infarction remodeling in mice.
In the study, animals treated with the Company's non-invasive medical device one or two times per day for 28 days had significantly smaller (by 36.4%, p<0.01) infarcts versus the controls. Furthermore, animals treated with Pulsed Electromagnetic Fields (PEMF) one or two times per day for 28 days demonstrated significantly less cardiac fibrosis than the controls.
Blood levels of Brain Natriuretic Peptide (BNP), a hormone secreted by cardiomyocytes in the heart in response to volume expansion and pressure overload, were significantly higher in animals treated two times per day with PEMF versus the controls. Natriuretic peptides have been shown to be Cardioprotective, anti-fibrotic and paracrine regulators of vascular regeneration. The Company is currently conducting a follow-up study to elucidate a possible mechanism of action of PEMF treatment. Specifically, the Company is examining if PEMF treatment promotes cardiomyocyte survival and wound repair (angiogenesis), and inhibits excessive inflammation in the infarcted heart.
The Company had previously announced initial pre-clinical data demonstrating Immunotronics™ significantly improved cardiac function, including ejection fraction and fractional shortening, and reduced ventricular remodeling in infarcted animals following myocardial infarction.
Left ventricular (LV) remodeling after myocardial infarction (MI) includes infarct expansion and hypertrophy of the non-infarcted myocardium, fibrosis, LV chamber dilatation, LV functional deterioration and progression to heart failure. Treatments targeting the remodeling process, such as beta-blockers and angiotensin converting enzyme inhibitors have been shown to improve LV function as well as long term survival. However, a slow progression to chronic heart failure continues with large transmural MI as the loss of infarcted tissue and volume overload (chamber dilation) is often out of proportion to the hypertrophic response. Therefore, new treatments that can further improve the remodeling process are critical for preventing heart failure following MI.
"We are truly astounded by the results of this study to evaluate the effectiveness of our Electroceuticals in improving heart function and reducing ventricular remodeling following MI," stated Endonovo CEO, Alan Collier.
"Our team has seen the benefits of non-invasive Electroceuticals in a clinical setting in patients with end-stage ischemic heart disease using our 27.12 MHz tPEMF platform. We have now taken over twenty years of research and development and have created a new technology that we believe is a more effective treatment for cardiovascular disease."
"We believe bioelectronic medicine is the future and our non-invasive Electroceuticals™ are at the forefront of this emerging field of medicine seeking to treat some of our largest causes of death, including cardiovascular and cerebrovascular disease with technology rather than drugs," concluded Mr. Collier.
The Company has posted an updated presentation containing the results of its pre-clinical study on the Presentations section of its website.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ addresses wound healing, pain, post surgical edema and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ device using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease, cardiovascular and peripheral artery disease. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108
Sbarnes@endonovo.com
www.endonovo.com
Source: Endonovo Therapeutics, Inc.
Investors: Sign Up for Email Alerts on Endonovo
Primary Logo
Source: Endonovo Therapeutics, Inc.
Released February 1, 2018
(2)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
WORDS TO LIVE BY:
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.